Wall Street Zen Downgrades vTv Therapeutics (NASDAQ:VTVT) to Sell

vTv Therapeutics (NASDAQ:VTVT) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “sell” rating in a research note issued on Saturday.

Several other analysts also recently issued reports on VTVT. Zacks Research downgraded shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. BTIG Research raised their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. HC Wainwright decreased their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday. Rodman & Renshaw initiated coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price target for the company. Finally, Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, vTv Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Price Performance

vTv Therapeutics stock opened at $35.37 on Friday. vTv Therapeutics has a 12 month low of $14.00 and a 12 month high of $44.00. The company’s fifty day simple moving average is $33.40 and its 200-day simple moving average is $34.80. The stock has a market cap of $139.36 million, a P/E ratio of -33.37 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, equities research analysts expect that vTv Therapeutics will post -2.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On vTv Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics in the 4th quarter valued at about $221,000. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the fourth quarter valued at about $731,000. Finally, Geode Capital Management LLC boosted its holdings in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after buying an additional 12,896 shares during the last quarter. Institutional investors own 17.51% of the company’s stock.

Trending Headlines about vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $42 price target for vTv Therapeutics. The target remains above the stock’s recent trading level, signaling that the analyst sees potential upside tied to the company’s biotechnology pipeline. HC Wainwright Cuts vTv Therapeutics Price Target to $42.00
• Neutral Sentiment: HC Wainwright’s $42 target is unchanged, but its revised estimates indicate that the company may continue reporting substantial losses. The analyst now expects 2026 earnings of ($0.97) per share, compared with a previous estimate of $0.02, and projects losses through 2030. HC Wainwright earnings estimates for vTv Therapeutics
• Negative Sentiment: HC Wainwright lowered its quarterly forecasts to losses of ($1.01) per share for Q3 2026 and ($0.89) for Q4 2026. Longer-term estimates were also reduced, including 2027 EPS to ($4.60), 2028 EPS to ($4.40), 2029 EPS to ($3.78), and 2030 EPS to ($3.61). The cuts suggest higher expected expenses or a slower path toward profitability. HC Wainwright lowers vTv Therapeutics earnings estimates
• Negative Sentiment: Wall Street Zen downgraded VTVT to Sell, adding bearish pressure to the investment outlook. The downgrade is especially notable because vTv Therapeutics recently reported a quarterly loss that was wider than analysts expected. vTv Therapeutics downgraded by Wall Street Zen to Sell

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.